
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is well-positioned to continue its strong performance with a solid portfolio of high-quality products, a diverse revenue stream, and a focus on continuous improvement. Although there are potential risks such as slow recovery in bioprocess equipment demand and challenges in the Chinese diagnostic market, the company's strong Q4 respiratory contribution, updated revenue growth expectations, and positive long-term outlook for their bioprocessing franchise indicate potential for continued growth in the future. Furthermore, their culture of continuous improvement and efficient business system are key strengths that will contribute to the company's success. Overall, Danaher is a strong company with a positive outlook for the future.
Bears say
Danaher is facing challenges in their life sciences and diagnostics divisions, including slower than expected growth in their biotechnology segment and delays in large shipments for programs at commercial customers. In addition, there is uncertainty in the industry with other players performing well and increasing competition, which may affect Danaher's sales processes. However, they have shown strong performance in their life sciences segment and have room for growth with potential acquisitions. There is also potential for growth in their bioprocess business, but there are risks associated with this. The company is making efforts towards sustainable practices and has a mixed track record for acquisitions. Overall, the company's growth potential is uncertain, and there are risks and challenges that may hinder their future performance.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares